Stem Cell Group Denies Selling Fraudulent Treatments

Law360, New York (January 17, 2017, 9:43 PM EST) -- A stem cell therapy provider accused of wrongfully marketing and selling stem cell treatments to patients nationwide told a California federal judge Monday to scrap the proposed fraud class action, calling it nothing more than a “fishing expedition.”

StemGenex Medical Group Inc. wants the court to dismiss the suit for failing to make any specific fraud allegations and for bringing conclusory claims against the defendants, which include some of StemGenex’s executives. The plaintiffs — people who were treated by StemGenex — have said that they wouldn’t...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.